| Low PDE4A expression promoted the progression of ovarian cancer by inducing Snail nuclear translocation. | Low PDE4A expression promoted the progression of ovarian cancer by inducing Snail nuclear translocation.
Wang J, Gu Q, Liu Y, Huang X, Zhang J, Liu B, Li R, Linghu H. | 06/27/2024 |
| Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology. | Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology.
Zahra N, Rafique S, Naveed Z, Nadeem J, Waqas M, Ali A, Shah M, Idrees M. | 04/27/2024 |
| PDE4 Gene Family Variants Are Associated with Response to Apremilast Treatment in Psoriasis. | PDE4 Gene Family Variants Are Associated with Response to Apremilast Treatment in Psoriasis.
Liadaki K, Zafiriou E, Giannoulis T, Alexouda S, Chaidaki K, Gidarokosta P, Roussaki-Schulze AV, Tsiogkas SG, Daponte A, Mamuris Z, Bogdanos DP, Moschonas NK, Sarafidou T., Free PMC Article | 04/1/2024 |
| Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models. | Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
Louveau B, Reger De Moura C, Jouenne F, Sadoux A, Allayous C, Da Meda L, Bernard-Cacciarella M, Baroudjian B, Lebbé C, Mourah S, Dumaz N. | 03/4/2024 |
| Increased expression of phosphodiesterase 4 in activated hepatic stellate cells promotes cytoskeleton remodeling and cell migration. | Increased expression of phosphodiesterase 4 in activated hepatic stellate cells promotes cytoskeleton remodeling and cell migration.
Elnagdy M, Wang Y, Rodriguez W, Zhang J, Bauer P, Wilkey DW, Merchant M, Pan J, Farooqui Z, Cannon R, Rai S, Maldonado C, Barve S, McClain CJ, Gobejishvili L., | 11/22/2023 |
| Reduction of Neutrophil Activation by Phosphodiesterase 4 Blockade in Behcet's Disease. | Reduction of Neutrophil Activation by Phosphodiesterase 4 Blockade in Behçet's Disease.
Le Joncour A, Régnier P, Maciejewski-Duval A, Charles E, Barete S, Fouret P, Rosenzwajg M, Klatzmann D, Cacoub P, Saadoun D. | 08/31/2023 |
| Phosphodiesterase (PDE) 4 inhibition boosts Schwann cell myelination in a 3D regeneration model. | Phosphodiesterase (PDE) 4 inhibition boosts Schwann cell myelination in a 3D regeneration model.
Schepers M, Malheiro A, Gamardo AS, Hellings N, Prickaerts J, Moroni L, Vanmierlo T, Wieringa P. | 08/25/2023 |
| Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins. | Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins.
Tibbo AJ, Mika D, Dobi S, Ling J, McFall A, Tejeda GS, Blair C, MacLeod R, MacQuaide N, Gök C, Fuller W, Smith BO, Smith GL, Vandecasteele G, Brand T, Baillie GS., Free PMC Article | 05/14/2022 |
| Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation. | Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation.
Dolce B, Christ T, Grammatika Pavlidou N, Yildirim Y, Reichenspurner H, Eschenhagen T, Nikolaev VO, Kaumann AJ, Molina CE., Free PMC Article | 10/23/2021 |
| The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. | The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease.
Wilson H, Pagano G, Niccolini F, Muhlert N, Mehta MA, Searle G, Gunn RN, Rabiner EA, Foltynie T, Politis M. | 09/11/2021 |
| Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro. | Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro.
Schmetterer KG, Goldhahn K, Ziegler LS, Gerner MC, Schmidt RLJ, Themanns M, Zebedin-Brandl E, Trapin D, Leitner J, Pickl WF, Steinberger P, Schwarzinger I, Marculescu R., Free PMC Article | 10/10/2020 |
| these results suggest that FCPR16 (PDE4 Inhibitor)is effective in protecting SH-SY5Y cells and neurons against oxidative stress via AMPK-dependent autophagy. Our findings indicate the potential application of FCPR16 in Parkinson's disease (PD) treatment. | Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP(+)-induced oxidative insult.
Zhong J, Xie J, Xiao J, Li D, Xu B, Wang X, Wen H, Zhou Z, Cheng Y, Xu J, Wang H. | 05/23/2020 |
| These findings suggest that autophagy induces TGF-b1 expression and EMT in hepatocarcinoma cells via cAMP/PKA/CREB signalling, which is activated by autophagy-dependent PDE4A degradation | Autophagy induces transforming growth factor-β-dependent epithelial-mesenchymal transition in hepatocarcinoma cells through cAMP response element binding signalling.
Hu S, Wang L, Zhang X, Wu Y, Yang J, Li J., Free PMC Article | 12/14/2019 |
| In human large intestinal circular muscle, the intracellular pathway of 5-HT4 receptors facilitating cholinergic neurotransmission to large intestinal circular smooth muscle is controlled by phosphodiesterase 4. | Synergy between 5-HT(4) receptor stimulation and phosphodiesterase 4 inhibition in facilitating acetylcholine release in human large intestinal circular muscle.
Pauwelyn V, Ceelen W, Lefebvre RA. | 10/26/2019 |
| PDE4 and Epac1 expression levels are increased in rectal carcinoma tissues, suggesting that the two proteins may be involved in the development of this malignancy. Meanwhile, correlations between PDE4 and Epac1, PDE4 and Cx43, PDE4 and cyclin E1, and Epac1 and Cx43 suggested synergistic effects of these proteins in promoting rectal carcinoma. | PDE4 and Epac1 Synergistically Promote Rectal Carcinoma via the cAMP Pathway.
Kong X, Ai G, Wang D, Chen R, Guo D, Yao Y, Wang K, Liang G, Qi F, Liu W, Zhang Y., Free PMC Article | 08/31/2019 |
| lack of AIP hinders the upregulation of PDE4A8 and PDE4A4 protein seen in sporadic somatotrophinomas. | Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Bizzi MF, Pinheiro SVB, Bolger GB, Schweizer JROL, Giannetti AV, Dang MN, Ribeiro-Oliveira A Jr, Korbonits M. | 05/4/2019 |
| FCPR16 is a novel PDE4 inhibitor with little emetic potential...Our findings indicate that FCPR16 is a promising pre-clinical candidate for the treatment of PD and possibly other oxidative stress-related neuronal diseases. | Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP(+)-induced decline of mitochondrial membrane potential and oxidative stress.
Zhong J, Yu H, Huang C, Zhong Q, Chen Y, Xie J, Zhou Z, Xu J, Wang H., Free PMC Article | 10/13/2018 |
| Here we describe a compound, BC54, that is a selective inhibitor of enzymes from the cAMP-specific PDE4 and PDE7 families. Consistent with the biological effect of other PDE4 and PDE7 inhibitors, BC54 displays potent anti-inflammatory properties and is superior to a combination of rolipram (a PDE4 inhibitor) and BRL50481 (a PDE7A inhibitor) for inducing apoptosis in chronic lymphocytic leukemia (CLL) cells | Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.
de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS., Free PMC Article | 06/16/2018 |
| Repurposing the PDE4 inhibitor roflumilast for treatment of B-cell malignancies is safe, suppresses the oncogenic PI3K/AKT kinases, and may be clinically active | Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
Kelly K, Mejia A, Suhasini AN, Lin AP, Kuhn J, Karnad AB, Weitman S, Aguiar RC., Free PMC Article | 02/10/2018 |
| The expression of PDE4A4 and PDE4A8 in normal pituitary, their increased expression in adenomatous pituitary cells where AIP is meant to participate, and the disruption of the PDE4A4-AIP interaction by AIP mutants may play a role in pituitary tumorigenesis. | cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
Bolger GB, Bizzi MF, Pinheiro SV, Trivellin G, Smoot L, Accavitti MA, Korbonits M, Ribeiro-Oliveira A Jr., Free PMC Article | 01/13/2018 |
| the well-known interaction between AIP and 2 different isoforms of phosphodiesterases (PDEs), PDE2A3 and PDE4A5, is of particular interest. While the interaction with over-expressed AIP does not seem to affect PDE2A3 function, the reported effect on PDE4A5 is, in contrast, reduced enzymatic activity. | Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants.
Hernández-Ramírez LC, Trivellin G, Stratakis CA. | 12/16/2017 |
| Low PDE4A expression is associated with sepsis. | Leukocyte phosphodiesterase expression after lipopolysaccharide and during sepsis and its relationship with HLA-DR expression.
Lelubre C, Medfai H, Akl I, Leentjens J, Kox M, Pickkers P, Rousseau A, Biston P, Piagnerelli M, Vanhaeverbeek M, Uzureau P, Vincent JL, Vanhamme L, Boudjeltia KZ. | 09/16/2017 |
| Findings demonstrate loss of PDE4 expression in the striato-thalamo-cortical circuit, which is associated with deficits of spatial working memory in patients with Parkinson disease. | Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
Niccolini F, Wilson H, Pagano G, Coello C, Mehta MA, Searle GE, Gunn RN, Rabiner EA, Foltynie T, Politis M. | 08/26/2017 |
| A multifunctional docking site on the catalytic unit of PDE4 that is utilized by multiple interaction partners has been identified. | Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners.
Houslay KF, Christian F, MacLeod R, Adams DR, Houslay MD, Baillie GS., Free PMC Article | 06/24/2017 |
| curcumin exerts its in vitro anti-angiogenic and in vivo anti-tumour properties through combined PDE2 and PDE4 inhibition | Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition.
Abusnina A, Keravis T, Zhou Q, Justiniano H, Lobstein A, Lugnier C. | 12/19/2015 |